Research Output Journal of Biological and Applied Science 4(3):1-5, 2024

ROJBAS Publications ONLINE ISSN: 1115-9200

https://rojournals.org/roj-biological-and-applied-science/ PRINT ISSN: 1115-6120

https://doi.org/10.59298/ROJBAS/2024/4315

Genetic Markers and Their Role in Predicting the Development of Benign Prostatic Hyperplasia (BPH)

Odile Patrick Thalia

Faculty of Biological Sciences Kampala International University Uganda

ABSTRACT

Benign prostatic hyperplasia (BPH) is a prevalent condition in aging men, characterized by the non-cancerous enlargement of the prostate gland, leading to bothersome lower urinary tract symptoms (LUTS) such as urinary urgency, frequency, and incomplete bladder emptying. While environmental and hormonal factors like androgen activity and chronic inflammation are well-known contributors to BPH development, genetic predisposition is increasingly recognized as a critical factor. A growing body of research has identified several genetic markers that may influence an individual's susceptibility to BPH. This review explores the current understanding of these genetic markers, focusing on key findings from genome-wide association studies (GWAS), single nucleotide polymorphisms (SNPs), and the role of epigenetic modifications such as DNA methylation and non-coding RNAs in the pathogenesis of BPH. Additionally, the review discusses the potential application of these genetic markers in the early prediction of BPH, which could facilitate more personalized and targeted approaches to treatment. Despite the advances in this field, challenges such as the clinical translation of genetic findings and the integration of genetic screening into routine practice remain. The future direction of BPH research will likely focus on refining predictive models and exploring novel therapeutic avenues based on genetic insights.

Key words: Genetic markers, benign prostatic hyperplasia, aging men, prostate gland, urinary tract, hormonal factors

INTRODUCTION

Benign prostatic hyperplasia (BPH) is a progressive, non-cancerous enlargement of the prostate gland, typically seen in aging men [1]. This condition is a major cause of lower urinary tract symptoms (LUTS), which include increased urinary frequency, urgency, nocturia (frequent urination at night), a weak urinary stream, and incomplete bladder emptying [2]. As the prostate enlarges, it can compress the urethra and obstruct urinary flow, leading to bothersome symptoms that significantly impact the quality of life. The prevalence of BPH increases with age, with approximately 50% of men over the age of 50 showing histological evidence of BPH, a number that rises to nearly 90% by the age of 80 [3,4]. Although not all men with histological BPH will develop symptomatic disease, BPH remains a leading cause of morbidity, with an estimated 30 million men worldwide affected by symptomatic BPH. The pathophysiology of BPH is multifactorial and complex. It is believed to result from a combination of hormonal dysregulation, chronic inflammation, and tissue remodeling [5]. As men age, the balance between androgens (such as testosterone and dihydrotestosterone) and estrogens shifts, promoting prostate tissue growth. In addition, chronic inflammation within the prostate may contribute to tissue remodeling and fibrosis, further exacerbating the enlargement of the gland [6]. Growth factors and cytokines involved in inflammatory and immune responses are thought to play significant roles in the progression of BPH [7]. Despite these well-established environmental and biological factors, it is increasingly evident that genetics also plays a critical role in the development and progression of BPH. Family studies and large-scale epidemiological research have provided strong evidence for a genetic predisposition to BPH. Men with a family history of BPH are at an increased risk of developing the condition, and studies involving twins have shown higher concordance rates among monozygotic

twins, reinforcing the notion that genetic factors contribute to the risk of developing BPH [8,9]. As the field of precision medicine continues to expand, understanding the genetic basis of BPH is of particular interest. Genetic markers offer the potential to identify individuals at higher risk for BPH earlier, allowing for more targeted prevention and personalized treatment strategies [10]. This review will summarize the current knowledge of genetic markers associated with BPH and explore their potential for early prediction and improved clinical management of the condition.

Overview of Genetic Factors in BPH Development

1. Genetic Predisposition to BPH

Genetic susceptibility to BPH has been demonstrated in familial studies, where men with a family history of BPH are more likely to develop the condition. The heritability of BPH is estimated to be 40-50%, indicating that genetic factors contribute significantly to its onset [11]. Large population-based studies have further reinforced the role of genetics in BPH, showing that men with first-degree relatives affected by BPH are at a higher risk of developing the condition [12].

2. Twin Studies and Population-Based Genetic Studies

Twin studies have provided compelling evidence for the genetic basis of BPH. In particular, monozygotic twins exhibit higher concordance rates for BPH compared to dizygotic twins, supporting the hypothesis of genetic inheritance [13]. Population studies, such as those conducted in large cohorts, have also identified familial clustering of BPH cases, suggesting that specific genetic variants may predispose individuals to the condition.

Advances in Genetic Markers for BPH Prediction

1. Single Nucleotide Polymorphisms (SNPs)

SNPs are variations at single nucleotide positions in the DNA sequence that can have functional consequences on gene expression and protein function [14]. Several SNPs have been associated with BPH risk. For example, polymorphisms in the SRD5A2 gene, which encodes the enzyme 5-alpha reductase responsible for converting testosterone to dihydrotestosterone (DHT), have been linked to BPH susceptibility [15]. Variations in the androgen receptor (AR) gene, which mediates the action of androgens in the prostate, are also implicated in BPH risk. Recent studies have identified SNPs in genes like GATA3, which is involved in immune regulation, and TGF-beta, a growth factor critical to prostate tissue remodeling [16]. These SNPs may provide valuable insights into the molecular mechanisms driving BPH and offer potential biomarkers for early detection.

2. Genome-Wide Association Studies (GWAS) in BPH

GWAS have revolutionized the study of complex diseases, including BPH. By scanning the entire genome for genetic variations associated with disease, GWAS have identified several loci linked to BPH risk [17]. Notably, genetic variants near the FGFR2 gene, which encodes a receptor involved in cell growth and differentiation, have been strongly associated with BPH [18]. Other GWAS findings point to regions involved in immune response and inflammation, reinforcing the role of chronic inflammation in BPH pathogenesis. GWAS have also uncovered multiple loci that overlap with other prostate conditions, such as prostate cancer, suggesting shared genetic pathways between BPH and malignancy [19]. These discoveries hold promise for developing risk prediction models based on polygenic risk scores.

3. Epigenetic Modifications and Their Role in BPH

Epigenetic modifications, such as DNA methylation, histone modifications, and non-coding RNA activity, play a key role in gene expression regulation without altering the underlying DNA sequence [20]. Epigenetic changes can be influenced by environmental factors and aging, which are critical in BPH development. For instance, aberrant DNA methylation patterns in genes involved in inflammation and growth regulation have been associated with BPH [21]. Non-coding RNAs, particularly microRNAs, have also emerged as regulators of prostate growth and may serve as biomarkers for BPH [22]. Altered expression of specific microRNAs has been linked to prostate tissue hyperplasia, highlighting the potential for epigenetic markers in BPH prediction.

Key Genetic Pathways Involved in BPH Pathogenesis

1. Androgen Receptor (AR) Pathway

Androgens, particularly DHT, are central to prostate growth and maintenance. The androgen receptor (AR) pathway is critical in mediating the effects of androgens on prostate cells [23]. Variations in the AR gene, particularly in its CAG repeat region, have been associated with altered androgen sensitivity and increased risk of BPH. Genetic studies have shown that individuals with shorter CAG repeats may be more prone to developing BPH due to enhanced AR activity [24].

2. Inflammation and Immune-Response Genes

Chronic inflammation is a well-recognized factor in BPH development. Several genetic markers related to inflammatory pathways have been identified in association with BPH. Variants in the IL-6 and TNF-alpha genes,

both of which encode pro-inflammatory cytokines, have been linked to increased prostate inflammation and BPH progression [25]. The role of immune regulation in BPH highlights the complex interplay between genetic predisposition and environmental triggers such as infection or hormonal imbalances.

3. Growth Factors and Cellular Proliferation Pathways

Growth factors such as fibroblast growth factor (FGF) and transforming growth factor-beta (TGF-beta) play a role in tissue remodeling and cellular proliferation in the prostate. Genetic variants in these pathways, particularly involving FGFR2 and TGF-beta signaling, have been associated with increased risk of prostate tissue overgrowth [26]. These pathways represent potential targets for future therapeutic interventions aimed at regulating abnormal prostate growth in BPH.

Clinical Application of Genetic Markers in BPH Prediction

1. Genetic Risk Scores for Predicting BPH

The concept of polygenic risk scores (PRS) has gained traction in predicting the risk of complex diseases like BPH. PRS combines the effects of multiple SNPs to estimate an individual's genetic predisposition to a condition [27]. By integrating genetic data from GWAS, PRS can stratify individuals into risk categories, identifying those at higher risk for BPH who may benefit from early screening and preventive interventions.

2. Personalized Medicine and Targeted Screening

The identification of genetic markers for BPH opens the door to personalized medicine. Genetic testing could be used to tailor screening protocols for individuals with a high genetic risk of BPH, allowing for earlier intervention and potentially reducing the need for invasive treatments later in life [28]. Personalized treatment approaches, such as targeting specific genetic pathways involved in prostate growth, could improve therapeutic outcomes and reduce side effects [29].

3. Challenges and Limitations in Clinical Implementation

Despite the potential benefits, there are significant challenges to the clinical implementation of genetic markers in BPH prediction. These include the cost of genetic testing, the need for large-scale validation of genetic risk models, and the ethical concerns surrounding genetic screening. Additionally, the multifactorial nature of BPH means that genetic markers alone may not be sufficient to predict disease with high accuracy, necessitating the integration of environmental and lifestyle factors into predictive models.

Future Directions in Genetic Research on BPH

1. Emerging Technologies in Genetic Research

The advent of new technologies such as CRISPR and next-generation sequencing offers exciting opportunities for advancing BPH research. These tools allow for the precise editing and analysis of genetic sequences, enabling researchers to identify and study rare variants that may contribute to BPH [30]. Future studies using these technologies could provide deeper insights into the genetic basis of BPH and identify novel therapeutic targets.

2. Integration of Multi-Omics Approaches

Combining genomics with other omics technologies such as transcriptomics, proteomics, and metabolomics may provide a more comprehensive understanding of BPH pathogenesis [31]. Systems biology approaches that integrate multi-omics data can help unravel the complex interactions between genes, proteins, and metabolites that drive prostate enlargement, potentially identifying new biomarkers and therapeutic targets [32].

3. Potential for Gene Therapy in BPH Management

Gene therapy, though in its infancy for BPH treatment, holds potential as a future therapeutic option [33]. By targeting specific genetic pathways involved in prostate growth, gene therapy could offer a more precise and less invasive treatment option for BPH. However, the ethical and practical challenges of gene editing in prostate health require careful consideration before clinical application.

CONCLUSION

The identification of genetic markers associated with BPH represents a significant advancement in understanding the genetic basis of this common condition. Genetic risk scores and personalized medicine approaches could revolutionize BPH management, offering more accurate risk prediction and tailored treatment options. However, further research is needed to validate these markers and overcome the challenges of clinical implementation

REFERENCES

1. Adediran AO, Olatunbosun EI. A descriptive study of prostate lesions in largest hospital In Ondo State of Nigeria. Global Journal of Health Sciences. 2020 Sep 10;5(2):18-39.
2. Beland L, Martin C, Han JS. Lower urinary tract symptoms in young men—causes and management. Current Urology Reports. 2022 Feb;23(2):29-37.

3. Ye Z, Wang J, Xiao Y, Luo J, Xu L, Chen Z. Global burden of benign prostatic hyperplasia in males aged 60–90 years from 1990 to 2019: results from the global burden of disease study 2019. BMC urology. 2024 Dec;24(1):1-5.
4. Ng M, Leslie SW, Baradhi KM. Benign prostatic hyperplasia. StatPearls [Internet]. 2024 Jan 11.
5. Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology. 2019 Aug 21;65(5):458-64.
6. Oseni SO, Naar C, Pavlović M, Asghar W, Hartmann JX, Fields GB, Esiobu N, Kumi-Diaka J. The molecular basis and clinical consequences of chronic inflammation in prostatic diseases: prostatitis, benign prostatic hyperplasia, and prostate Cancer. Cancers. 2023 Jun 8;15(12):3110.
7. Cao D, Sun R, Peng L, Li J, Huang Y, Chen Z, Chen B, Li J, Ai J, Yang L, Liu L. Immune cell proinflammatory microenvironment and androgen-related metabolic regulation during benign prostatic hyperplasia in aging. Frontiers in Immunology. 2022 Mar 21;13:842008.
8. Hung SC, Chang LW, Hsiao TH, Lin GC, Wang SS, Li JR, Chen IC. Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese. Human Genomics. 2024 May 22;18(1):49.
9. Lin KB, Wu MP, Lin YK, Yen YC, Chuang YC, Chin HY. Lifestyle and behavioral modifications made by patients with interstitial cystitis. Scientific Reports. 2021 Feb 4;11(1):3055.
10. Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022 Sep 5;27(17):5730.
11. Yue L, Wang T, Ge Y, Ge M, Zhang C, Hou Q, Wang W, Tian H, Ren B, Du B, Zhang W. Prevalence and heritability of benign prostatic hyperplasia and LUTS in men aged 40 years or older in Zhengzhou rural areas. The Prostate. 2019 Feb;79(3):312-9.
12. Samtal C, El Jaddaoui I, Hamdi S, Bouguenouch L, Ouldim K, Nejjari C, Ghazal H, Bekkari H. Review of prostate cancer genomic studies in Africa. Frontiers in Genetics. 2022 Oct 11;13:911101.
13. Aghamir SM, Aluru P, Fattahi B, Parsa G, Hosseini SR, Reis LO. Molecular biology, genetic, and epigenetics of prostate disease. InGenetics and Epigenetics of Genitourinary Diseases 2025 Jan 1 (pp. 111-123). Academic Press.
14. Deng NA, Zhou H, Fan H, Yuan Y. Single nucleotide polymorphisms and cancer susceptibility. Oncotarget. 2017 Dec 12;8(66):110635.
15. Zeng XT, Su XJ, Li S, Weng H, Liu TZ, Wang XH. Association between SRD5A2 rs523349 and rs9282858 polymorphisms and risk of benign prostatic hyperplasia: A meta-analysis. Frontiers in physiology. 2017 Sep 12;8:688.
16. Pillai M. The identification and study of transcription factors and co-factors other than androgen receptor that could have important role in the regulation of gene expression in prostate tumor (Master's thesis).
17. Li W, Klein RJ. Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk. Prostate Cancer and Prostatic Diseases. 2021 Jun;24(2):492-8.
18. Stangis MM, Colah AN, McLean DT, Halberg RB, Collier LS, Ricke WA. Potential roles of FGF5 as a candidate therapeutic target in prostate cancer. American Journal of Clinical and Experimental Urology. 2023;11(6):452.
19. Kerns SL, Fachal L, Dorling L, Barnett GC, Baran A, Peterson DR, Hollenberg M, Hao K, Narzo AD, Ahsen ME, Pandey G. Radiogenomics consortium genome-wide association study meta-analysis of late toxicity after prostate cancer radiotherapy. JNCI: Journal of the National Cancer Institute. 2020 Feb 1;112(2):179-90.
20. Bure IV, Nemtsova MV, Kuznetsova EB. Histone modifications and non-coding RNAs: mutual epigenetic regulation and role in pathogenesis. International Journal of Molecular Sciences. 2022 May 22;23(10):5801.
21. Joseph DB, Strand DW, Vezina CM. DNA methylation in development and disease: an overview for prostate researchers. American journal of clinical and experimental urology. 2018;6(6):197.
22. Lemos AE, da Rocha Matos A, Ferreira LB. The long non-coding RNA PCA3: an update of its functions and clinical applications as a biomarker in prostate cancer. Oncotarget. 2019 Nov 11;10(61):6589.
23. Vickman RE, Franco OE, Moline DC, Vander Griend DJ, Thumbikat P, Hayward SW. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review. Asian journal of urology. 2020 Jul 1;7(3):191-202.
24. Qin Z, Li X, Han P, Zheng Y, Liu H, Tang J, Yang C, Zhang J, Wang K, Qi X, Tang M. Association between polymorphic CAG repeat lengths in the androgen receptor gene and susceptibility to prostate cancer: A systematic review and meta-analysis. Medicine. 2017 Jun 1;96(25):e7258.

25. Santos-Pereira M, Pereira SC, Rebelo I, Spadella MA, Oliveira PF, Alves MG. Decoding the Influence of Obesity on Prostate Cancer and Its Transgenerational Impact. Nutrients. 2023 Nov 21;15(23):4858.
26. Ardizzone A, Bova V, Casili G, Repici A, Lanza M, Giuffrida R, Colarossi C, Mare M, Cuzzocrea S, Esposito E, Paterniti I. Role of basic fibroblast growth factor in cancer: biological activity, targeted therapies, and prognostic value. Cells. 2023 Mar 24;12(7):1002.
27. Ding Y, Hou K, Burch KS, Lapinska S, Privé F, Vilhjálmsson B, Sankararaman S, Pasaniuc B. Large uncertainty in individual polygenic risk score estimation impacts PRS-based risk stratification. Nature genetics. 2022 Jan;54(1):30-9.
28. Aghasipour M, Asadian F, Dastgheib SA, Shirinzadeh-Dastgiri A, Vakili-Ojarood M, Narimani N, Atarod MM, Haghighikian SM, Barahman M, Masoudi A, Shiri A. Familial Hereditary Prostate Cancer: Genetic, Screening, and Treatment Strategies.
29. Fenton SE, VanderWeeler DJ, Rebbeck TR, Chen DL. Advancing Prostate Cancer Care: Treatment Approaches to Precision Medicine, Biomarker Innovations, and Equitable Access. American Society of Clinical Oncology Educational Book. 2024 Jun;44(3):e433138.
30. McDonald G. Exploring CRISPR/Cas9 as a tool to investigate the role of Androgen Receptor in basal to luminal cell differentiation using human prostate cell lines (Doctoral dissertation, University of York).
31. Resurreccion EP, Fong KW. The integration of Metabolomics with other Omics: insights into understanding prostate Cancer. Metabolites. 2022 May 27;12(6):488.
32. Nevedomskaya E, Haendler B. From omics to multi-omics approaches for in-depth analysis of the molecular mechanisms of prostate cancer. International Journal of Molecular Sciences. 2022 Jun 3;23(11):6281.
33. Katsimperis S, Kapriniotis K, Manolitsis I, Bellos T, Angelopoulos P, Juliebø-Jones P, Somani B, Skolarikos A, Tzelves L. Early investigational agents for the treatment of benign prostatic hyperplasia'. Expert Opinion on Investigational Drugs. 2024 Apr 2;33(4):359-70.

CITE AS: Odile Patrick Thalia (2024). Genetic Markers and Their Role in Predicting the Development of Benign Prostatic Hyperplasia (BPH). Research Output Journal of Biological and Applied Science 4(3):1-5. https://doi.org/10.59298/ROJBAS/2024/4315